4,7,10,13,16,19-docosahexaenoic acid

Table of contents


On 3 November 2006, orphan designation (EU/3/06/412) was granted by the European Commission to Jose Manuel Cela Lopez, Spain, for 4,7,10,13,16,19-docosahexaenoic acid for the treatment of retinitis pigmentosa.

The sponsorship was transferred to Celavista Pharmaceuticals Limited, Ireland, in August 2011 and subsequently to Natac Pharma SL, Spain, in May 2013.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
4,7,10,13,16,19-docosahexaenoic acid
Intented use
Treatment of retinitis pigmentosa
Date of designation
Orphan designation status
EU designation number

Sponsor's contact details

Natac Pharma S.L.
C/ Faraday 7
28049 Madrid
Tel. +34 91 827 64 70
Fax +34 91 827 66 99

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating